Post-acute blood biomarkers and disease progression in Traumatic Brain Injury
Jussi P. Posti(University of Turku), D.K. Menon(University of Cambridge), Nicholas J. Ashton(King's College London), Joel Simrén(University of Gothenburg), M.M. Correia(University of Cambridge), B. Glocker(Imperial College London), D.A. Chatfield(University of Cambridge), A. Mankletow(University of Cambridge), K. Blennow(University of Gothenburg), A.J. Katila(University of Turku), E. Needham(University of Cambridge), R.S. Takala(University of Turku), O. Tenovuo(University of Turku), Henna-Rikka Maanpää(University of Turku), V.F. Newcombe(University of Cambridge), J. Frantzén(University of Turku), J. Tallus(University of Turku), H. Zetterberg(University of Gothenburg), G.B. Williams(University of Cambridge), S. Winzeck(University of Cambridge)
Cited by 1
Related Papers
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2021|354
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
|Nature Medicine|2022|349
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
|Nature Aging|2022|300